October 1, 2018

Rodin Therapeutics, Inc.

Acquired by NASDAQ: ALKS in Nov 2019

Rodin is developing a differentiated approach to Alzheimer’s through targeted epigenetic regulation of synaptic function and health by HDAC complex modulation. Developer of epigenetic drugs intended to be used for the treatment of cognitive disorders and diseases of the brain. The company's epigenetic drugs are harnessing the power of epigenetic regulation of neuronal function by HDAC complex modulation, enabling patients to restore synaptic function, health and survival in degenerative brain diseases.